Are You Ready To Pitch To Investors? Enter the RESI Europe Innovators’ Pitch Challenge

14 Feb

By Karen Deyo, Investor Research Analyst, LSN

LSN first introduced the Innovators’ Pitch Challenge at RESI Boston in September of 2018. This new aspect of RESI was designed to give the earliest stage companies spinning out from incubators, accelerators and universities a platform to pitch to a panel of investors.  The aim of the RESI Innovators’ Pitch Challenge was to give these companies a chance to practice their investment pitch and get valuable feedback from real investors. To get a perspective on the value of participating in the Innovators’ Pitch Challenge, I spoke to Scott Stout, CEO of MedVector Clinical Trials (one of the companies selected to participate in the West Coast Innovators’ Pitch Challenge at RESI San Francisco), and Ravi Mistry, an angel investor part of TiE Silicon Valley Angels, who was part of the investor panel at the same event.

Especially for those earliest stage companies just starting their first major fundraise, the ability to practice your pitch before a panel of investors can be helpful. The questions asked by the experienced investor panelists can help the participants anticipate what investors will ask when pitching to them, as well as helping you identify what areas of your pitch may need to be clarified. As an angel investor and very active mentor for entrepreneurs, Ravi pointed out how valuable an exercise this can be, both as a way to potentially catch the interest of the investor panelists, as well as a practice for the future. Ravi also noted that the diverse range of expertise the investors had, across all sectors of the life sciences, can be helpful to the exercise.

Beyond the value of practicing his pitch, Scott said that one of the major benefits of applying to and participating in the Pitch Challenge was the additional exposure he received via RESI’s website and on-site guide, and the ability to highlight to current and potential investors that their company was selected to participate by LSN’s scientific review team. This serves as valuable external validation of the company and technology.

To apply for the European Innovators’ Pitch Challenge, please fill out the application and make sure to indicate that you are a tech hub constituent!

Accelerating clinical trials speeds up medicine. MedVector is a turnkey solution using telemedicine to increase clinical trial participation, generate revenue for hospitals, reduce costs to clinical trial sponsors, and bring life-saving, advanced medicine to market more quickly.

Ravi Mistry, Member, TiE Angels

Ravi Mistry is a leader, entrepreneur, angel investor, educator and mentor. His professional career has spanned the life sciences, technology, non-profits, and academics as Founder, Board Chairman/Director, President, Vice President, Sr. Director, Manager, and Adjunct Professor. He brings experience covering all areas of business operations. He has managed closing of Seed, Series A/B funding totaling over $35M. Ravi served as VP/BizDev at MedTree, a life sciences start-up, and as Executive Director of Indian Institute of Technology Gandhinagar Foundation to raise endowment funds. Previously, Ravi was member of founding team of Virident Systems, a technology startup acquired by HGST/Western Digital. Ravi has held management positions in the life sciences companies DiscoveRx (acquired by Eurobond) and BioImagene (acquired by Roche). He is Gold Medalist from Gujarat University, India, with a bachelor’s degree in Engineering. He received his Master’s in Engineering from Stanford, and an MBA in Finance from CSUEB.

Gain Added Exposure at RESI Europe by Applying to the Innovation Challenge

14 Feb

By Jessica Yang, Senior Investor Research Analyst & Asia BD, LSN

Life Science Nation invites all early stage life science/healthcare companies to apply to the RESI Europe Innovation Challenge to showcase their technologies at our upcoming RESI partnering event in Vienna! Companies can apply to the Innovation Challenge free of charge. Once the applications close (the deadline is February 20th!), the LSN scientific review team selects the top 30 to compete. Innovation Challenge Finalists present a poster in the exhibition hall during RESI, as well as receiving additional exposure in the printed program guide and the LSN newsletter. All attendees receive ‘RESI cash’ which they can ‘invest’ in their favorite companies – the top three companies will receive prizes during the cocktail hour and will be announced to LSN’s worldwide following!

Here are some features of Innovation Challenge:

  • Finalists will be highlighted in multiple media outlets:
    • Announcement in weekly LSN Newsletter with readership of 20,000+
    • Featured on RESI Conference website
    • Featured in printed and online RESI Vienna program guide
  • Finalists will present a poster of their technology at the conference
  • All conference attendees will have the chance to “invest” RESI Cash in their favorite technologies
  • Top 3 winners will be announced during the cocktail reception and receive prizes/ RESI tickets to future RESI Conferences
  • It is FREE to apply!

Companies can apply through the online portal, with supplementary materials sent to The submission deadline is February 20th, 2019.

Also check out to see how to be successful in the RESI Innovation Challenge:

Here is a testimonial from the 1st place in the Innovation Challenge at last RESI Conference:

The inaugural RESI Europe conference will occur in Vienna on March 25th at the Vienna Marriott Hotel, and we are excited to receive your Innovation Challenge application!

Life Science Investors Converge on RESI Europe: Meet the Early Stage Therapeutics Panelists

14 Feb

By Lucy Parkinson, VP of Investor Research, LSN

LSN’s one overriding message is that entrepreneurs need to look globally for capital. That’s the ethos that guides RESI, and our Investor Research team maintain a network of investors based all over the world that regularly attend our RESI partnering events to meet with emerging CEOs. RESI’s first ever event in Europe is already attracting a high level of investor interest – Click here to see some of the firms that are confirmed to attend RESI Europe to look for early stage opportunities. Due to RESI’s laser focus on investment, there’s no more efficient way to connect with global capital – entrepreneurs can book up to 16 investor meetings in one day, and RESI’s unique partnering system helps get their messages to the most relevant investors in their space.

In addition to meetings, RESI provides two tracks of investor panels that help entrepreneurs understand how life science investors think, what they’re looking for, and what makes a deal go or no-go for them. RESI’s Early Stage Therapeutics panel will cover all these issues and more for biotech entrepreneurs. The participants are:

Sara Secall (Investment Director, Inveready Asset Management)

Sara is responsible for building the Biotech Portfolio. She led the negotiation of ZIP Solutions license to a world top-3 bioprocessing company based in Germany which led to ZIP Solutions’ sale to Bionaturis. She sits at the board of Agrasys, Avizorex, BDI, Innoup Pharma, Leukos, Oncostellae, VLP and is a Board Observer at Edesa Biotech. She worked for Chevron Technology Ventures, the corporate Venture Capital group based in California with USD 210 MM under management. As Director of Spin Outs for the University of Barcelona, she was involved in starting and financing over 25 technology start ups and she negotiated numerous technology licenses. She has worked extensively in the USA, Latin America and Europe. Sara holds a BS in Chemistry, MSc from Indiana University and an MBA from the London Business School.

Marco Boorsma (Partner, Forbion)

Marco is Partner at Forbion Capital Partners and joined the firm in 2007. He has a background in molecular biology and biotechnology and brings operational and business development experience from both small and large businesses. Before joining Forbion Marco was Business Development Director and project manager at DSM Pharmaceutical Products and scientist at Cytos Biotechnology in Switzerland. He serves on the Board of Directors of Inflazome, NorthSea Therapeutics, Milestone Pharmaceuticals, Escalier Biosciences, RSPR Pharma, and Engene. After obtaining a master’s degree in molecular biology from the University of Groningen, Marco received his PhD in biotechnology from the ETH Institute for Technology in Zürich, and completed part of his research at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge, UK.

Harvey Gross (Partner, Apollo Ventures)

Harvey is a Partner at Apollo Ventures, a life science venture capital firm and life science company builder working across Europe and North America. At Apollo, Harvey is working on the meaningful and future focused topic of health and biomedicine to make a difference. At Apollo, Harvey combines his entrepreneurial spirit and enthusiasm for finance to assess business opportunities and assist portfolio companies with strategy and venture development. Before joining Apollo, Harvey worked at the investment bank Lazard, where he conducted M&A activities on both buy and sell side mandates. He was also one of the first employees at the FinTech startup N26, where he was responsible for talent acquisition and setting up the customer support function. During his studies he co-founded his first NGO and has launched two other tech startups. Harvey holds a degree in International Business with a major in Finance from Maastricht University.

Martin Pfister (Senior Investment Manager: Life Sciences, High-Tech Gründerfonds)

Dr. Martin Pfister joined the High-Tech Gründerfonds (HTGF) Medtech/LifeSciences team in Bonn in 2010. HTGF is the largest Seedfonds in Europe with about 900 Mio EUR under management and an active portfolio of about 260 technology-based portfolio companies, about 95 of which are in life sciences.


  • studied a combination of Medicine and Pharmacy in Germany and New York University, Medical School with a PhD in Immunology
  • Started his career in the hospital/laboratory
  • moved to the start-up life sciences world 18 years ago.
  • co-founded two companies in the molecular Dx field (VC backed, Exit) and healthcare services (privately owned, Exit 2018)
  • @ HTGF manages a portfolio of 13 life science companies including Biotech, Medtech and digital health
  • holds board member seat in 4 companies including clinical stage Biotech

Roel Bulthuis (Managing Director, INKEF Capital)

Roel Bulthuis is a Managing Director and head of the Healthcare investment team at INKEF Capital. Roel combines close to 20 years of experience across venture capital, pharma business development and M&A and healthcare investment banking. Prior to joining INKEF he served as SVP and Managing Director of M-Ventures which he created and developed into a leading CVC fund. Prior to that, he served in senior positions in global business development and M&A at Merck Serono and in the healthcare investment banking team at Fortis Bank. Roel is a Kauffman Fellow and passionate about continuously challenging the status quo. Roel holds a Msc. in Biopharmaceutical Sciences from Leiden University and an MBA in Finance from the Helsinki School of Economics.

%d bloggers like this: